« Return to News | Drug Sponsors

Shire joins ABPI

Tuesday, August 21, 2012 09:56 AM

Specialty biopharmaceutical company Shire has joined the Association of the British Pharmaceutical Industry (ABPI) as a full member.

"Shire is a fast growing company with high ambitions and our U.K. business continues to evolve; we seek to play a role in the development and growth of our industry so joining the ABPI will be one way of contributing to this,” said Nicola Massey vice president and general manager of the U.K. International Speciality Business and Janis Clayton vice president and general manager of the U.K. Human Genetics Therapy Business, Shire. “We are looking forward to working with the ABPI and engaging with their wider membership on issues that are important to all of us but most importantly to fight for the needs of our patients."

Nicola Massey will join the ABPI board of management with immediate effect.

Stephen Whitehead, chief executive of the ABPI, said, "I’m delighted Shire has joined the ABPI. This is a critical time for industry and a very important time for our members. The ABPI provides a strong voice and strong leadership for our members and we are very happy to be supporting Shire as we go forward."

Shire is focused on chronic symptomatic diseases in areas of unmet needs where the impact of their medicines can make an immediate and tangible difference for patients.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.